The government is now operating in accordance with the Guidance on Caretaker Conventions, pending the outcome of the 2025 federal election.
NERLYNX (Specialised Therapeutics PM Pty Ltd)
Product name
NERLYNX
Date registered
Evaluation commenced
Decision date
Approval time
200 working days (255)
Active ingredients
neratinib maleate
Registration type
NCE/NBE
Indication
NERLYNX (film coated tablets) is indicated for the extended adjuvant treatment of adult patients with early-stage HER2-overexpressed/amplified breast cancer, to follow adjuvant trastuzumab based therapy.